Navigation Links
SCOLR Pharma, Inc. Announces Final Closing of Private Placement
Date:6/30/2011

BOTHELL, Wash., June 30, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today announced that it has closed the second and final tranche of its previously-announced private placement of its 8% Senior Secured Convertible Debentures due 2013 (the "Debentures").  The Company raised a total of $1,190,200 in the offering.  The Company intends to use the net proceeds for working capital and other general corporate purposes.

Stephen J. Turner, President and Chief Executive Officer, said: "The completion of this offering will allow us to continue to focus on the development of our nutritional business and on our efforts to secure licensing or partnership support for our pharmaceutical products.  We are making good progress in placing our nutritional products on retail shelves and this capital will enable us to be even more aggressive in those efforts."

This second tranche consisted of the sale of an additional $189,000 principal amount of Debentures.  The Debentures, together with accrued and unpaid interest, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of common stock.  Beginning after the date that is six months from the issuance of the Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of common stock.  The Debentures bear interest of 8% per annum, compounded quarterly, and are secured by all the Company's assets.  The Company may, at any time and from time to time, upon 10 days prior notice to the holders, pay in cash all or a portion of the accrued and unpaid interest on the Debentures, or may cause conversion of such accrued and unpaid interest in connection with any mandatory conversion of the Debentures.


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
7. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
8. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
9. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
10. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... 2 Sanofi-aventis announced,today that one year ... STEEPLE,studies confirm clear net clinical benefit for ... for Lovenox(R) vs,Unfractionnated Heparin (UFH). The ... were presented during,hotline sessions at the European ...
... Researchers at the National Institute of Standards ... calibration tools to help correct and validate ... substances based on fluorescence. , Recent ... the development and use of fluorescence-based analytic ...
... governments biodefense efforts, the potential for terrorists to cause ... years after the letter attacks that shook the nation ... University of Michigan Medical School have developed the first ... inside unwitting immune cells their supposed attackers ...
Cached Biology Technology:New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2Taming the anthrax threat 2Taming the anthrax threat 3
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... living sensor that can spot contamination. They have also ... even in previously untreatable cold areas, microbiologists heard today ... Microbiology,s Autumn meeting being held this week at Trinity ... in the sub-arctic. It contains over 230,000 tonnes of ...
... a new method to fabricate borosilicate glass ... nanoparticles are more stable when subjected to ... currently used nanoparticles made of polymers or ... range of potential nanoparticle applications in biomedical, ...
... MD The Biophysical Society is pleased to announce ... recipients will receive their awards at the Society,s 53rd ... Boston Convention and Exhibitions Center in Massachusetts. The awardees ... California, San Francisco, will receive the Anatrace Membrane Protein ...
Cached Biology News:Living sensor can warn of arsenic pollution 2Biophysical Society names 2009 award recipients 2